Loading...
•
Dec 31, 2020
Evolent Health Q4 2020 Earnings Report
Evolent Health reported a revenue increase of 15.0% year-over-year, achieved adjusted EBITDA of $16.1 million, and experienced a net loss attributable to common shareholders of $(14.6) million.
Key Takeaways
Evolent Health announced its Q4 and full-year 2020 results, revealing a 15.0% increase in GAAP revenue to $271.9 million for the quarter. The company achieved an adjusted EBITDA of $16.1 million, but reported a net loss attributable to common shareholders of $(14.6) million. Evolent also added new regional physician group partners and expanded its partnership with Blue Cross Blue Shield of Texas.
GAAP revenue increased by 15.0% year-over-year to $271.9 million.
Net loss attributable to common shareholders was $(14.6) million.
Adjusted EBITDA reached $16.1 million.
Lives on Full Platform of approximately 3.6 million and New Century Health Technology & Services Suite of 6.2 million
Evolent Health
Evolent Health
Forward Guidance
The Company is providing forward-looking guidance for the Services business only. Revenue for the year ending December 31, 2021 is expected to be in the range of approximately $830.0 million to $880.0 million. Adjusted EBITDA is expected to be in the range of approximately $40.0 million to $50.0 million.
Positive Outlook
- Revenue for the year ending December 31, 2021 is expected to be in the range of approximately $830.0 million to $880.0 million.
- Adjusted EBITDA is expected to be in the range of approximately $40.0 million to $50.0 million.
- For the three months ending March 31, 2021, revenue is expected to be in the range of approximately $205.0 million to $215.0 million.
- Adjusted EBITDA is expected to be in the range of approximately $10.0 million to $14.0 million.
- Company to report True Health results as a discontinued operation in 2021
Challenges Ahead
- Actual results may differ materially.
- Factors that may cause actual results to differ materially from our current expectations are set forth below in "Forward Looking Statements - Cautionary Language" and Evolent Health, Inc.'s filings with the Securities and Exchange Commission ("SEC").
- The pending sale of True Health New Mexico
- Uncertainty in the health care regulatory framework, including the potential impact of policy changes
- Evolution in the market for value-based care